Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2006-03-14
2006-03-14
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S482000, C424S489000, C424S494000
Reexamination Certificate
active
07011849
ABSTRACT:
Formulations are provided herein which allow for a once daily dosing regimen for amoxicillin and clavulanic acid.
REFERENCES:
patent: 4110165 (1978-08-01), Cole et al.
patent: 4282202 (1981-08-01), Dowrick
patent: 4301149 (1981-11-01), Crowley
patent: 4303582 (1981-12-01), Shean et al.
patent: 4441609 (1984-04-01), Crowley
patent: 4525352 (1985-06-01), Cole et al.
patent: 4537887 (1985-08-01), Rooke et al.
patent: 4673637 (1987-06-01), Hyman
patent: 4950484 (1990-08-01), Olthoff et al.
patent: 5051262 (1991-09-01), Panoz et al.
patent: 5077790 (1991-12-01), Shell
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5158779 (1992-10-01), Gergely et al.
patent: 5225197 (1993-07-01), Bolt et al.
patent: 5407686 (1995-04-01), Patel et al.
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5487901 (1996-01-01), Conte et al.
patent: 5500227 (1996-03-01), Oshlack et al.
patent: 5582837 (1996-12-01), Shell
patent: 5650169 (1997-07-01), Conte et al.
patent: 5670170 (1997-09-01), Grimmett
patent: 5681583 (1997-10-01), Conte et al.
patent: 5690959 (1997-11-01), Palepu et al.
patent: 5733577 (1998-03-01), Myers et al.
patent: 5738874 (1998-04-01), Conte et al.
patent: 5741524 (1998-04-01), Stanisforth et al.
patent: 5814337 (1998-09-01), Merrifield et al.
patent: 5849330 (1998-12-01), Marvola et al.
patent: 5851550 (1998-12-01), Martin et al.
patent: 5858412 (1999-01-01), Stanisforth et al.
patent: 5861172 (1999-01-01), Martin et al.
patent: 5910322 (1999-06-01), Rivett et al.
patent: 5962022 (1999-10-01), Bolt et al.
patent: 5972389 (1999-10-01), Shell et al.
patent: 6051254 (2000-04-01), Merrifield et al.
patent: 6051255 (2000-04-01), Conley et al.
patent: 6077536 (2000-06-01), Merrifield et al.
patent: 6110497 (2000-08-01), Martin et al.
patent: 6126969 (2000-10-01), Shah et al.
patent: 6136345 (2000-10-01), Grimmett et al.
patent: 6177421 (2001-01-01), Moir et al.
patent: 6183778 (2001-02-01), Conte et al.
patent: 6183780 (2001-02-01), Van Balken et al.
patent: 6214359 (2001-04-01), Bax
patent: 6294199 (2001-09-01), Conley et al.
patent: 6294200 (2001-09-01), Conte et al.
patent: 6299903 (2001-10-01), Rivett et al.
patent: 6340475 (2002-01-01), Shell et al.
patent: 6352720 (2002-03-01), Martin et al.
patent: 6358528 (2002-03-01), Grimmett et al.
patent: 6372255 (2002-04-01), Saslawski et al.
patent: 6399086 (2002-06-01), Katzhendler et al.
patent: 2001/0018070 (2001-08-01), Shell et al.
patent: 2001/0026809 (2001-10-01), Oshlack et al.
patent: 2001/0038838 (2001-11-01), Burch
patent: 2001/0043926 (2001-11-01), Burch
patent: 2001/0046984 (2001-11-01), Rudnic
patent: 2001/0048944 (2001-12-01), Rudnic et al.
patent: 2002/0001616 (2002-01-01), Conley et al.
patent: 2002/0004071 (2002-01-01), Cherukuri
patent: 2002/0004499 (2002-01-01), Rudnic et al.
patent: 2002/0006433 (2002-01-01), Davidson et al.
patent: 2002/0064562 (2002-05-01), Martin et al.
patent: 2002/0086056 (2002-07-01), Grimmett et al.
patent: 0080862 (1983-09-01), None
patent: 0131147 (1985-01-01), None
patent: 0222914 (1987-05-01), None
patent: 0234670 (1987-09-01), None
patent: 0389177 (1988-09-01), None
patent: 0396335 (1990-11-01), None
patent: 0131147 (1996-12-01), None
patent: 0281200 (1996-12-01), None
patent: 1044680 (2000-10-01), None
patent: 1508977 (1978-04-01), None
patent: 2005538 (1979-04-01), None
patent: 205 611 (1991-04-01), None
patent: WO 91/15197 (1991-10-01), None
patent: WO 92/19227 (1992-11-01), None
patent: WO 93/00898 (1993-01-01), None
patent: WO 93/00898 (1993-01-01), None
patent: WO 94/06416 (1994-03-01), None
patent: WO 94/16696 (1994-08-01), None
patent: WO 94/27557 (1994-12-01), None
patent: WO 94/27600 (1994-12-01), None
patent: WO 95/20946 (1995-08-01), None
patent: WO 95/25516 (1995-09-01), None
patent: WO 95/28148 (1995-10-01), None
patent: WO 95/28927 (1995-11-01), None
patent: WO 95/33487 (1995-12-01), None
patent: WO 96/04907 (1996-02-01), None
patent: WO 96/04908 (1996-02-01), None
patent: WO 96/07408 (1996-03-01), None
patent: WO 96/34605 (1996-11-01), None
patent: WO 96/34605 (1996-11-01), None
patent: WO 97/09042 (1997-03-01), None
patent: WO 98/05305 (1998-02-01), None
patent: WO 98/07424 (1998-02-01), None
patent: WO 98/22091 (1998-05-01), None
patent: WO 98/35672 (1998-08-01), None
patent: WO 98/40054 (1998-09-01), None
patent: WO 98/42311 (1998-10-01), None
patent: WO 99/25343 (1999-05-01), None
patent: WO 99/47125 (1999-09-01), None
patent: WO 99/62910 (1999-12-01), None
patent: WO 00/03695 (2000-01-01), None
patent: WO 00/12088 (2000-03-01), None
patent: WO 00/23045 (2000-04-01), None
patent: WO 00/41478 (2000-07-01), None
patent: WO 00/44353 (2000-08-01), None
patent: WO 00/61116 (2000-10-01), None
patent: WO 01/00177 (2001-01-01), None
patent: WO 01/56544 (2001-08-01), None
patent: WO 01/62231 (2001-08-01), None
patent: WO 01/80824 (2001-11-01), None
Appelbaum, 1996, “Epidemiology and in vitro susceptibility of drug-resistantStreptococcus pneumoniae,” Ped. Inf. Dis. J., 15(10): 932-939.
Brooks et al., “Pleuromutilins, Part 1: The Identification of Novel 14-Carbamates”, Bioorganic and Medicinal Chemistry 9, 2001, pp. 1221-1231.
Catherall et al., “Distribution and Efficacy Studies with Ticarcillin-Clavulanic Acid(Timentin) in ExperimentalKlebsiella pneumoniaeMeningitis in Rabbits”, Journal of Chemotherapy, 1989 supplement No. 4, pp. 80-81.
Chiou, “Critical Evaluation of the Potential Error in Pharmacokinetic Studies of Using the Linear Trapezoidal Rule Method for the Calculation of the Area Under the Plasma Level-Time Curve,” 1978, J. Pharmicokinet. Biopharm., 6(6): 539-546.
Everett et al., “19F NMR Spectroscopy Study of the Metabolites of Flucloxacillin in Rat Urine,” Journal of Pharm. Pharmacology, 1985, vol. 37, pp. 869-873.
Everett et al., “A Study of Flucloxacillin Metabolites in Rat Urine by Two-Dimensional1H,19F COSY NMR,” Journal of Pharmaceutical & Biomedical Analysis, 1989, vol. 7, No. 3, pp. 397-403.
Everett et al., “Spin-echo1H N.M.R. spectroscopy: A new method for studying penicillin metabolism,” J. Chem. Soc. Chem. Commun., 1984, pp. 894-895.
Hannan et al., “In Vitro Activity of Gemifloxacin (SB 265805; LB 20304a) against human mycoplasmas,” Journal of Antimibrobial Chemotherapy, 2000, vol. 45, pp. 367-369.
Ji et al., “Identification of Critical Staphylococcal Genes Using Conditional Phenotypes Generated by Antisense RNA”, Science Reprint, Sep. 21, 2001, vol. 293, pp. 2266-2269.
Ji et al., “Regulated Antisense RNA Eliminates Alpha-Toxin Virulence inStaphylococcus aureusInfection”, Journal of Bacteriology, Nov. 1999, pp. 6585-6590.
Mizeri et al., “Simulation of Human Serum Pharmacokinetics of Ticarcillin-Clavulanic Acid and Ceftazidime in Rabbits and Efficacy Against ExperimentalKlebsiella pneumoniaeMeningitis”, Antimicrobial Agents and Chemotherapy, May 1989, vol. 33, No. 5, pp. 693-699.
Slocombe et al., “In Vitro and In Vivo Activity of Temocillin”, Research and Clinical Forums, vol. 12, No. 5, pp. 21-31.
Woodnutt et al., “Acetate entry rate into portal and peripheral blood in the rabbit”, Proc. Nutr. Soc., 1979, vol. 38, p. 72A.
Woodnutt et al., “Acetate Metabolism By Tissues of the Rabbit”, Comp. Biochemical Physiol, 1986, vol. 85B, No. 2, pp. 487-490.
Woodnutt et al., “Pharmacokinetics and Distribution of Ticarcillin-Clavulanic Acid (Timentin) in Experimental Animals”, Antimicrobial Agents and Chemotherapy, 1987, vol. 31, No. 11, pp. 1826-1830.
Woodnutt et al., “Rabbit liver acetyl-CoA synthetase”, Biochem. J., 1978, vol. 175, pp. 757-759.
Woodnutt et al., “Simulation of Human Serum Pharmacokinetics of Cefazolin, Piperacillin, and BRL 42715 in Rats and Efficacy Against Experimental Intraperitoneal Infections”, Antimicrobial Agents and Chemotherapy, Jul. 1992, vol. 36, No. 7, pp. 1427-1431.
Woodnutt et al., “Temocillin Efficacy in ExperimentalKlebsiella pneumoniaeMeningitis after Infusion into Rabbit Plasma
Conley Creighton P.
Roush John A.
Storm Kevin H.
Beecham Pharmaceuticals (Pte) Limited
Dinner Dana L.
Kinzig Charles M.
Page Thurman K.
Venetianer Stephen
LandOfFree
Second release phase formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Second release phase formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Second release phase formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3573421